Consolidating North American Mental Health Services and Research.
15 Established Clinics Plus Clinical Research Division and Partners.
Extensively Experienced Interim CEO Recently Appointed.
Completed Acquisition of Integrated Rehab and Performance to Treat Veterans and First Responders.
Engaged in Groundbreaking Immersive Virtual Reality R&D Program.
KetamineOne Capital Limited (NEO: MEDI, OTC: KONEF, Frankfurt: MY0) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. MEDI is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, MEDI has a network of 15 clinics across North America, with plans to further consolidate the highly fragmented industry. The recent addition of KGK Science Inc. as the MEDI contract research division also places the company at the forefront of premium clinical research based on its 23-year history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, MEDI is dedicated to helping solve the growing need for safe and accessible mental health therapy.
MEDI Announces Adam Deffett as Interim CEO
On July 7th MEDI announced that its Board of Directors has appointed Adam Deffett as the Company’s Interim Chief Executive Officer (“CEO”). Mr. Deffett will continue to perform his duties as VP Capital Markets while holding the title of Interim CEO. MEDI has launched a search process to identify appropriate candidates and ultimately hire a permanent CEO to lead the Company, which it expects to complete in the coming months.
Adam Deffett is a senior capital markets professional with over 15 years of experience in the Canadian equity markets. Mr. Deffett began his career at RBC Capital Markets and has held senior positions in both sales and trading at various Canadian banks and independent dealers. He has extensive experience in capital raising, shareholder communication, and capital markets strategy. Mr. Deffett graduated with a Bachelor of Commerce from the University of Calgary and is a CFA Charterholder.
MEDI Highlights Psychedelic Research and Announces New Clinical Trial
On June 17th MEDI provided guidance on several new strategic initiatives on behalf of its wholly-owned contract research organization, KGK Science Inc., (“KGK” or the “CRO”). KGK is rapidly being integrated into the MEDI mental health platform, accelerating the ability to foster value creation through the Company’s clinic portfolio, grow its work with existing third-party clients and establish a leadership position in psychedelic research and clinical trial work. Being at the forefront of psychedelics research strongly positions MEDI and KGK to generate defendable intellectual property and secure first mover advantages. Further, MEDI is pleased to report that KGK has recently been awarded a new clinical trial contract, a research project, and has also completed two studies.
Psychedelic Research Highlights:
Working with five unique clients in psychedelic drug studies including but not limited to Numinus (TSXV: NUMI) and Psyched Wellness (CSE: PSYC).
Conducting two ongoing clinical trials, one of which is the previously announced preliminary study of Numinus’ proprietary psilocybin mushroom extract in healthy adults.
Developing a network of vertically-integrated clinics within MEDI for the conduct of psychedelic clinical trials. This will be a critical step in it achieving its goal of becoming the premier CRO in the psychedelic medicine industry and integrating with MEDI clinical assets.
Collaborating with Zentrela, the maker of the Cognalyzer™, to adapt the device for use in psychedelic medicine with the goal of providing the sector with a revolutionary tool to be used in human research and the clinical application of psychedelic drugs.
Improving virtual trial conduct through the implementation of a novel platform and technology with the other subsidiaries of MEDI, which is expected to be launched over the next year.
Working with the Ontario-based contract manufacturer Acenzia to provide a joint solution for the production and study of psychedelic compounds and final products. Acenzia plans to produce psychedelic mushrooms as well as formulate and manufacture psychedelic products at their EU GMP-accredited facility.
New Proposals, Recent Wins, and Completed Work:
Emerging from COVID-related restrictions, KGK is seeing significant growth in new projects and requests for proposals, including a substantial expansion in psychedelics-related work. Requests for proposals and other quotes have increased by almost 60 percent over the past 12 months as compared to the same prior period.
Recently awarded a clinical testing trial for two novel human milk oligosaccharides produced by a large Japanese firm.
Contracted to facilitate preclinical studies of a novel vitamin ingredient, the results of which are planned to be used to support the submission of a New Dietary Ingredient Notification to the US FDA.
Anticipated to complete a clinical trial investigating the efficacy of a multi-ingredient formulation on self-reported memory complaints in healthy adults in the fall of 2021. KGK has extensive experience in conducting clinical trials in the areas of cognition and stress and plans on pursuing more work in this growing area of research.
Year to date, completed two pharmacokinetic clinical studies for nutraceutical products.
MEDI Closes Acquisition of Integrated Rehab and Performance
On June 15th MEDI announced that it has closed its previously announced acquisition of Integrated Rehab and Performance Ltd. (“IRP”). Pursuant to the terms of the definitive agreement, MEDI has acquired 100% of the outstanding and issued shares of IRP, and IRP’s Founder and Chief Executive Officer (“CEO”), Steven Inglefield, has become a director of MEDI.
The acquisition is expected to provide locations across the MEDI clinical network with the benefits of a model honed through 10,000 unique treatments for past or present personnel of the Canadian Armed Forces and the Royal Canadian Mounted Police, as well as first responders including firefighters, law enforcement officers, paramedics, and emergency medical technicians. Beyond IRP’s primary location in Victoria, British Columbia, MEDI will next begin treating military veterans and first responders at its Halifax clinic with plans to apply IRP’s treatment model and best practices at other clinics in locations with a higher population density of veterans and first responders. The resulting treatments are expected to combine the efficacy of multidisciplinary pain management and physical therapy with the MEDI ketamine-assisted mental health approaches and psychedelic medicines.
Immersive Virtual Reality R&D Program at MindScape Clinic
On June 7th MEDI announced that its wholly-owned MindScape facility (“MindScape or the “Clinic”) in Houston, Texas has recently become one of the first centers of its kind to introduce and explore Immersive Virtual Reality (“IVR”) as a way to enhance patient experiences as part of ketamine-assisted treatments (the “R&D Program”). The MEDI R&D Program being performed at MindScape will advance the creation of a proprietary IVR platform for deployment across the Company’s entire North American network of clinics.
The addition of IVR to MindScape’s treatment offering further diversifies its services and marks a milestone as the MEDI Clinic’s most innovative initiative to date. The sensory-enhancing nature of IVR has been proven to help patients suffering from mental illness, and has been shown to reduce relapses1. Clinic patients who select IVR-based treatments will receive a tailored therapy plan that includes a determination of their mental state and individual goals. With over 2,000 treatments administered since inception, MindScape also recently expanded its service offering to provide spa-like therapeutic treatment experiences.
MEDI is also working to offer patients across its clinical network an integrated system experience that includes the use of various wearable technologies, which are expected to enable clinicians to personalize treatments as well as identify and respond to changes in a patient’s wellbeing in real-time. Further, through its recently acquired KGK Science division, MEDI is planning to launch clinical studies later this year to explore the potential for IVR to improve treatment outcomes in patients.
Additionally, MEDI announced that it has appointed Dr. Quang Henderson to its strategic advisory board. Dr. Henderson has also been appointed Chair of the MEDI newly formed Clinic Innovation Council (the “CIC”). The CIC is a cross-functional governance body comprised of clinic leaders, working towards the goal of determining and implementing best practices and innovative technologies across the MEDI network of medical clinics, with the overarching mission of improving patient outcomes.
For more information on KetamineOne Capital Limited (NEO: MEDI, OTC: KONEF) visit:https://www.ketamine.one and https://equity.guru/2021/07/ketamine-one-capital-medi-ne-is-converting-cannabis-clinics-into-ketamine-clinics/
DISCLAIMER:
CAP/FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CAP/FPS/CA is NOT affiliated in any manner with any company mentioned herein. CAP/FPS/CA is a news dissemination solutions provider and is NOT a registered broker/dealer/analyst/adviser, holds no investment licenses, and may NOT sell, offer to sell or offer to buy any security. CAP/FPS/CA’s market updates, news alerts, and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. CAP/FPS/ CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CAP/FPS/CA has been compensated $500 by a third party for dissemination of this article.
Disclaimer/Safe Harbor:
These news releases and postings may contain forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.
Media Contact
Company Name: KETAMINEONE CAPITAL LTD
Contact Person: Media Relations
Email: Send Email
Phone: +1 604-687-2038
Address:810 – 789 West Pender Street
City: Vancouver
State: BC V6C 1H2
Country: Canada
Website: https://www.ketamine.one/
